［1］BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］GARG T,MCMULLEN CK,LEO MC,et al.Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle nvasive bladder cancer in a multisite,community-based cohort［J］.Cancer,2021,127(4):520-527.
［3］ROSENBERG JE,O'DONNELL PH,BALAR AV,et al.Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy［J］.Journal of Clinical Oncology,2019,37(29):2592-2600.
［4］HOIMES CJ,FLAIG TW,MILOWSKY MI,et al.Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer［J］.J Clin Oncol,2023,41(1):22-31.
［5］BALAR AV,CASTELLANO DE,GRIVAS P,et al.Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma:Results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up［J］.Ann Oncol,2023,34(3):289-299.
［6］POWLES T,PARK SH,CASERTA C,et al.Avelumab first-line maintenance for advanced urothelial carcinoma:Results from the JAVELIN bladder 100 trial after ≥2 years of follow-up［J］.J Clin Oncol,2023,41(19):3486-3492.
［7］VAN DER HEIJDEN MS,SONPAVDE G,POWLES T,et al.Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma［J］.N Engl J Med,2023,389(19):1778-1789.
［8］SHOLL LM.Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer［J］.Mod Pathol,2022,35(Suppl 1):66-74.
［9］KLUMPER N,WUST L,SAAL J,et al.PD-L1(CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma［J］.Oncoimmunology,2023,12(1):2267744.
［10］DE JONG MME,KELLERMAYER Z,PAPAZIAN N,et al.The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape［J］.Nat Immunol,2021,22(6):769-780.
［11］KUMARASAMY C,SABARIMURUGAN S,MADURANTAKAM RM,et al.Prognostic significance of blood inflammatory biomarkers NLR,PLR,and LMR in cancer-A protocol for systematic review and Meta-analysis［J］.Medicine,2019,98(24):e14834.
［12］EBERST G,VERNEREY D,LAHEURTE C,et al.Prognostic value of CD4+T lymphopenia in non-small cell lung cancer［J］.BMC Cancer,2022,22(1):529.
［13］RABOLD K,GIELEN PR,KERS-REBEL ED,et al.T-cell lymphopenia in patients with advanced thyroid carcinoma is associated with poor prognosis［J］.Oncologist,2019,24(3):e106-e110.
［14］DENG W,XU C,LIU A,et al.The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy［J］.Radiother Oncol,2019,133:9-15.
［15］GALDIERO MR,VARRICCHI G,LOFFREDO S,et al.Roles of neutrophils in cancer growth and progression［J］.J Leukoc Biol,2018,103(3):457-464.
［16］RAO HL,CHEN JW,LI M,et al.Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis［J］.PLoS One,2012,7(1)：e30806.
［17］MENETRIER-CAUX C,RAY-COQUARD I,BLAY JY,et al.Lymphopenia in cancer patients and its effects on response to immunotherapy:An opportunity for combination with cytokines［J］.J Immunother Cancer,2019,7(1):85.
［18］童晶涛,张欢乐,郑璐,等.血小板和淋巴细胞的比值,中性粒细胞和淋巴细胞的比值与非小细胞肺癌的临床病理学关系及预后效果研究［J］.中国卫生检验杂志,2019,29(24):3020-3023.
TONG JT,ZHANG HL,ZHENG L,et al.Clinicopathological relationship between PLR,NLR and non-small cell lung cancer and the research on prognostic efficacy［J］.Chinese Journal of Health Laboratory Technology,2019,29(24):3020-3023.
［19］MIYAMA Y,KANEKO G,NISHIMOTO K,et al.Lower neutrophil-to-lymphocyte ratio and positive programmed cell death ligand-1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma［J］.Cancer Med,2022,11(22):4236-4245.
［20］TOMIOKA-INAGAWA R,NAKANE K,ENOMOTO T,et al.The impact of neutrophil-to-lymphocyte ratio after two courses of pembrolizumab for oncological outcomes in patients with metastatic urothelial carcinoma［J］.Biomedicines,2022,10(7):1609.
［21］MALAKA AMERATUNGA,MAXIME CHENARD POIRIER,IRENE MORENO CANDILEJO,et al.Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors［J］.European Journal of Cancer,2018,89:56-63.
［22］ALONA ZER,MIKE R SUNG,PREET WALIA,et al.Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer［J］.Clin Lung Cancer,2018,19(5):426-434.
［23］EDMUND K BARTLETT,JESSICA R FLYNN,KATHERINE S PANAGEAS,et al.High neutrophil-to-lymphocyte ratio(NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy［J］.Cancer,2020,126(1):76-85.
［24］KURASHINA R,ANDO K,INOUE M,et al.Platelet-to-lymphocyte ratio predicts the efficacy of pembrolizumab in patients with urothelial carcinoma［J］.Anticancer Res,2022,42(2):1131-1136.
［25］QI YL,LIAO DX,FU XM,et al.Elevated platelet to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy［J］.Int Immunopharmacol,2019,74:105707.
［26］El-MOSALAMY H,SALMAN TM,ASHMAWEY AM,et al.Role of chronic E.Coli infection in the process of bladder cancer-An experimental study［J］.Infectious Agents and Cancer,2012,7(1):19.
［27］AKHTAR S,AL-SHAMMARI A,AL-ABKAI J.Chronic urinary tract infection and bladder carcinoma risk:A Meta-analysis of case-control and cohort studies［J］.World J Urol,2018,36(6):839-848.
［28］BAYNE CE,FARAH D,HERBST KW,et al.Role of urinary tract infection in bladder cancer:A systematic review and Meta-analysis［J］.World J Urol,2018,36(8):1181-1190.
［29］刘梅娟.血清LPS、CRP、PCT水平检测在肾结石术后尿路感染中的诊断价值［J］.首都医药,2019,26(13):75.
LIU MJ.Diagnostic value of serum LPS,CRP and PCT levels in postoperative urinary tract infections after kidney stone surgery［J］.Capital Medicine,2019,26(13):75.